Search results for "Inhibitor protein"

showing 10 items of 63 documents

Hereditary Angioedema with Normal C1 Inhibitor

2013

Until recently it was assumed that hereditary angioedema was a disease that results exclusively from a genetic deficiency of the C1 inhibitor. In 2000, families with hereditary angioedema, normal C1 inhibitor activity, and protein in plasma were described. Since then, numerous patients and families with that condition have been reported. Most of the patients were women. In many of the affected women, oral contraceptives, hormone replacement therapy containing estrogens, and pregnancies triggered the clinical symptoms. In some families mutations in the coagulation factor XII (Hageman factor) gene were detected.

Malemedicine.medical_specialtyImmunologyCoagulation Factor XIIC1-inhibitorDiagnosis DifferentialPregnancyRisk FactorsInternal medicinemedicineHumansImmunology and AllergyHereditary Angioedema Type IIIAngioedemaFactor XIIbiologyAngioedemabusiness.industryAngioedemas Hereditarymedicine.diseaseEndocrinologyTransgender hormone therapyFactor XIIMutationHereditary angioedemabiology.proteinFemaleDifferential diagnosismedicine.symptombusinessComplement C1 Inhibitor ProteinImmunology and Allergy Clinics of North America
researchProduct

C1-ESTERASE INHIBITOR REVERSES FUNCTIONAL CONSEQUENCES OF SUPERIOR MESENTERIC ARTERY ISCHEMIA/REPERFUSION BY LIMITING REPERFUSION INJURY AND RESTORIN…

2006

Activated complement contributes significantly to reperfusion injury after ischemia. This study explores functional consequences of C1-esterase inhibitor (C1-INH) treatment after superior mesenteric artery occlusion (SMAO)/ reperfusion using intravital microscopy. Thirty anesthetized, spontaneously breathing, male Sprague-Dawley rats underwent SMAO for 60 min followed by reperfusion (4 h). C1-esterase inhibitor (100 and 200 IU/kg body weight) or saline (0.9%) was given as a single bolus before reperfusion. Sham-operated animals (n = 10) without SMAO served as controls.Systemichemodynamicsweremonitoredcontinuously,arterial bloodgasesanalyzedintermittently, andleukocyte/ endothelial interacti…

Malemedicine.medical_treatmentIschemiaPharmacologyCritical Care and Intensive Care MedicineRats Sprague-DawleyBolus (medicine)Mesenteric Artery Superiormedicine.arterymedicineAnimalsSuperior mesenteric arterySalinebusiness.industryMicrocirculationMetabolic acidosismedicine.diseaseRatsRegional Blood FlowMesenteric ischemiaReperfusion InjuryAnesthesiaEmergency MedicinebusinessComplement C1 Inhibitor ProteinReperfusion injuryIntravital microscopyShock
researchProduct

Research on complement: old issues revisited and a novel sphere of influence

2003

Immunology in recent years has taken a somewhat surprising turn, expressed by a renewed interest in innate immunity. Especially intriguing is the regulatory role exerted by the innate components on the adaptive response, with Toll receptors and complement components being the most investigated. This function has been firmly established for complement protein CR2 (CD21) as part of the BCR co-receptor CD19/CD21/CD81. New findings are now providing a broader picture of complement and its tuning of the immune response; for example, complement proteins have been implicated in the control of T-cell-mediated responses. We will review some of these data here and summarize new discoveries in areas o…

Membrane GlycoproteinsInnate immune systemT-LymphocytesImmunologychemical and pharmacologic phenomenaComplement System ProteinsComplement C1 Inactivator ProteinsBiologyImmunity InnateComplement componentsComplement systemComplement (complexity)Membrane Cofactor ProteinImmune systemAntigens CDComplement Factor HImmunologyAnimalsHumansImmunology and AllergyKidney DiseasesSphere of influenceComplement C1 Inhibitor ProteinSerpinsTrends in Immunology
researchProduct

Mechanisms of Raf-1 Kinase Inhibitor Protein Dysregulation in Triple-Negative Breast Cancers and Identification of Possible Novel Therapeutic Approac…

2014

Triple-negative breast cancers (TNBCs) are a heterogenous group of breast cancers characterized by poor prognosis because they are not amenable to targeted therapies. We have taken into account that altered expression of Raf-1 kinase inhibitor protein (RKIP), a tumor and metastasis suppressor and a promoter of drug-induced apoptosis, is frequent in TNBCs and may be involved in their aggressive biology. Interestingly, the analysis of the possible mechanisms of RKIP downregulation in TNBCs permits the identification and recapitulation of different possible approaches, including epigenetic modulation, e.g., by DNA demethylating agents or histone deacetylase inhibition, and NF-κB inhibition. Th…

Oncologymedicine.medical_specialtybiologybusiness.industryCyclin-dependent kinase 4Settore MED/06 - Oncologia MedicaInhibitor proteinBiochemistryEpigenetic therapy NF-κB inhibition Raf-1 kinase inhibitor protein triple-negative breast cancersInternal medicineRaf 1 kinaseGeneticsbiology.proteinCancer researchSettore BIO/14 - FarmacologiaMolecular MedicineMedicineIdentification (biology)businessTriple negativeEpigenetic therapyBiotechnology
researchProduct

Evaluation of the IKKβ Binding of Indicaxanthin by Induced-Fit Docking, Binding Pose Metadynamics, and Molecular Dynamics

2021

Background: Indicaxanthin, a betaxanthin belonging to the betalain class of compounds, has been recently demonstrated to exert significant antiproliferative effects inducing apoptosis of human melanoma cells through the inhibition of NF-κB as the predominant pathway. Specifically, Indicaxanthin inhibited IκBα degradation in A375 cells. In resting cells, NF-κB is arrested in the cytoplasm by binding to its inhibitor protein IκBα. Upon stimulation, IκBα is phosphorylated by the IKK complex, and degraded by the proteasome, liberating free NF-κB into the nucleus to initiate target gene transcription. Inhibition of the IKK complex leads to the arrest of the NF-κB pathway.Methods: To acquire deta…

PharmacologyMolecular modelChemistryAllosteric regulationIKKβMetadynamicsindicaxanthinInhibitor proteinRM1-950Settore CHIM/08 - Chimica Farmaceuticamolecular dynamicsIκBαchemistry.chemical_compoundanticancer activityProteasomeDocking (molecular)Settore BIO/10 - BiochimicaBiophysicsbinding pose metadynamicsPharmacology (medical)induced fit dockingTherapeutics. PharmacologyIndicaxanthinOriginal ResearchFrontiers in Pharmacology
researchProduct

Current drugs in early development for hereditary angioedema: potential for effective treatment

2014

Hereditary angioedema (HAE) through C1 inhibitor deficiency is a rare but important disease. It is characterized by recurrent episodes of angioedema, which commonly affects the skin (in the form of swelling in the extremities, face and genitals) as well as the gastrointestinal tract (abdominal pain attacks). In approximately 1% of cases of angiodema-related swelling, there is obstruction of the upper airway, which is potentially life-threatening. Therefore, HAE due to C1 inhibitor deficiency may be associated with significant morbidity and mortality. Recent research has added to our ever-increasing understanding of the pathogenesis of HAE, which has, in addition, new clinical trials with ne…

Pharmacologymedicine.medical_specialtyGastrointestinal tractAbdominal painAngioedemabusiness.industryAngioedemas HereditaryGeneral MedicineDiseasemedicine.diseaseDermatologySurgeryClinical trialPathogenesisTreatment OutcomeHereditary angioedemamedicineAnimalsHumansPharmacology (medical)medicine.symptomAirwaybusinessComplement C1 Inhibitor ProteinExpert Opinion on Investigational Drugs
researchProduct

Kel1 is a phosphorylation-regulated noise suppressor of the pheromone signaling pathway.

2021

Abstract Mechanisms have evolved that allow cells to detect signals and generate an appropriate response. The accuracy of these responses relies on the ability of cells to discriminate between signal and noise. How cells filter noise in signaling pathways is not well understood. We have analyzed noise suppression in the yeast pheromone signaling pathway. By combining synthetic genetic array screening, mass spectrometry and single-cell time-resolved microscopy, we discovered that the poorly characterized protein Kel1 serves as a major noise suppressor of the pathway. At the molecular level, Kel1 suppresses spontaneous activation of the pheromone response by inhibiting membrane recruitment of…

Programmed cell deathSaccharomyces cerevisiae ProteinsChemistryCellbiologiCell BiologySaccharomyces cerevisiaeSynthetic genetic arrayGeneral Biochemistry Genetics and Molecular BiologyPheromonesCell biologylaw.inventionlawFus3SuppressorPhosphorylationPheromoneSignal transductionMitogen-Activated Protein KinasesPhosphorylationNoiseSte5Adaptor Proteins Signal TransducingCyclin-Dependent Kinase Inhibitor ProteinsSignal TransductionCell reports
researchProduct

Proteomics of Galápagos Marine Iguanas Links Function of Femoral Gland Proteins to the Immune System

2020

Femoral glands secrete a wax-like substance on the inner side of lizard hind legs, which is thought to function as a mode of chemical communication. Though the minor volatile fraction is well studied, the major protein fraction remains enigmatic. Here, we use proteomics to analyze proteins in femoral gland secretions of the Galápagos marine iguana. Although we found no evidence for proteins and peptides involved in chemical communication, we found several immune-regulatory proteins which also demonstrate anti-microbial functions. Accordingly, we show that femoral gland proteins and peptides function as a barrier against microbial infection and may prevent the rapid degradation of volatile s…

ProteomicsProteomeProteomicsBiochemistryAnalytical ChemistryAnti-Infective AgentsTandem Mass Spectrometrydatabase designprotease inhibitor protein identificationLungSkin0303 health sciencesMuscles030302 biochemistry & molecular biologyBrainHigh-Throughput Nucleotide SequencingHeartBlood proteinsanimal modelsmarine iguanaBiochemistryOrgan SpecificityProteomeEcuadorBacillus subtilisPulmonary Surfactant-Associated ProteinsGalectinsAntileukoproteinaseBiologyprotease inhibitor03 medical and health sciencesproteomicsImmune systemfemoral glandsevolutionEndopeptidasesEscherichia coliAnimalsHumanstissuesMolecular Biology030304 developmental biologyGalectinInnate immune systemChemotactic FactorsResearchMyocardiumImmunity Innateimmune systemIguanasMuramidaseApoproteinsTranscriptomeFunction (biology)Molecular & Cellular Proteomics
researchProduct

Treatment with C1-esterase inhibitor concentrate in type I or II hereditary angioedema: a systematic literature review.

2013

Hereditary angioedema (HAE) due to C1 esterase inhibitor (HAE-C1-INH) deficiency is a rare genetic disorder presenting with recurrent episodes of skin swellings, abdominal pain attacks, and potentially fatal laryngeal edema. This study was designed to review the efficacy and safety of pasteurized, human, plasma-derived C1-INH concentrate for the treatment of patients with HAE-C1-INH. A systematic search of electronic databases up to December 2011 was performed without language or date restrictions. Two reviewers completed the study selection using predefined inclusion criteria, tabulated, and analyzed the data. The data were inappropriate for meta-analysis; thus, a qualitative synthesis was…

Pulmonary and Respiratory MedicineAdultMaleAbdominal painmedicine.medical_specialtyAdolescentPlacebolaw.inventionYoung AdultQuality of lifeRandomized controlled triallawInternal medicineImmunology and AllergyMedicineHumansYoung adultChildRandomized Controlled Trials as TopicHereditary Angioedema Types I and IIbusiness.industryGeneral Medicinebacterial infections and mycosesmedicine.diseaseSystematic reviewTreatment OutcomeChild PreschoolHereditary angioedemaObservational studyFemalemedicine.symptombusinessComplement C1 Inhibitor ProteinAllergy and asthma proceedings
researchProduct

Efficacy of C1 esterase inhibitor concentrate in treatment of cutaneous attacks of hereditary angioedema.

2015

BACKGROUND Although treatment with C1 esterase inhibitor (C1-INH) concentrate is well established for hereditary angioedema (HAE) attacks in general, data that assess its efficacy for cutaneous attack treatment are sparse. OBJECTIVE To assess efficacy of plasma-derived, nanofiltered C1-INH concentrate for cutaneous attack treatment by comparing treated attacks from the uncontrolled I.M.P.A.C.T.2 study with historical data for untreated attacks. METHODS Cutaneous attack data from patients with HAE who were treated for cutaneous edema with 20 IU/kg body weight C1-INH concentrate in the uncontrolled I.M.P.A.C.T.2 study (38 patients) were compared with data from untreated patients from an histo…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAdolescentUntreated groupPeripheral edemaGastroenterologySeverity of Illness IndexYoung AdultInternal medicineSeverity of illnessmedicineImmunology and AllergyHumansYoung adultChildAgedEnd pointbusiness.industryAngioedemas HereditaryGeneral MedicineArticlesMiddle Agedmedicine.diseasePeripheralC1 esteraseTreatment OutcomeHereditary angioedemaDisease ProgressionFemalemedicine.symptombusinessComplement C1 Inhibitor ProteinAllergy and asthma proceedings
researchProduct